The ISTH 1999 Congress in Washington, D.C., marked an ending: the final ISTH event of the millennium. However, for Cecile Denis, Ph.D., and Peter Lenting, Ph.D., the ISTH 1999 Congress marked the beginning: the first meeting that led to a relationship, which has withstood long distances and lasted more than 20 years.
On Monday, July 19, 2021, Dillon Bohinc of Case Western Reserve University School of Medicine in Cleveland presented results from research aimed at developing a therapeutic strategy that specifically targets activated, pathogenic neutrophil subsets without the ubiquitous inhibition of resting cells.
Emilie Montenont, Ph.D., of The University of Utah commented that the goal of her research was to develop and define the strengths and limitations of a rapid and systematic approach to screen genes for platelet functions in primary megakaryocytes called CRIMSON.
Numerous studies have established that thrombosis is a common complication for cancer patients. Unfortunately, a uniform biomarker does not exist and the current risk scoring methods exhibit modest accuracy. Machine learning may be able to help.
On Sunday, July 19, 2021, Carlo Zaninetti of the Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald in Germany, presented results on the comparison between immunofluorescence and genetic testing for diagnosing inherited platelet disorders (IPDs).
On Monday, July 19, 2021, Larry Goldfinger of Thomas Jefferson University in Philadelphia presented follow-up research on the inhibitory role for platelets in solid tumor growth mediated by tumor infiltration of platelet microvesicles (microparticles), which are enriched in platelet-derived microRNAs (miRNAs).
On Tuesday, July 20, 2021, Hanny Al-Samkari, M.D., of Massachusetts General Hospital in Boston presented results on oral pazopanib for severe hereditary hemorrhagic telangiectasia (HHT)-associated bleeding.
On Wednesday, July 21, 2021, Manuela Albisetti, Head of the Hemophilia Center of the University Children’s Hospital in Zurich, Switzerland, presented results from research that looked at the efficacy and safety of dabigatran in treatment and secondary prevention of venous thromboembolism (VTE) in children with central venous catheter (CVC)- or implantable device (ID)-related thrombosis.
Sign up to get the latest news and updates from the ISTH Congress delivered to your inbox.
By submitting this form, you are granting: The International Society on Thrombosis and Haemostasis, 610 Jones Ferry Road, Suite 205 Carrboro, North Carolina 27510 USA,
http://www.isth.org permission to email you. You may unsubscribe via the link found at the bottom of every email.